AI 聊天
Loading data for SION — first visit, this takes a few seconds.

Sionna Therapeutics, Inc.

SION · NasdaqGM · USD

7.48 +0.18 (2.47%)

收盘价: Sep 11, 2026, 8:00 PM

7.85 +0.00%

盘后: 7:59 PM

市值
$354.4M
下次财报日期
Nov 5, 2026

Sionna Therapeutics, Inc.(SION)股价、分析与数据

内在价值

正在加载内在价值…

分析师预测

股票预测 →

分析师预测不可用

12个月目标价 · n/a 位分析师

分析师一致意见: n/a

时间间隔:1D
正在加载K线和信号…

财务表现

查看财务 →

加载中...

最新财报

已公布较预期同比变动
营收$0n/an/a
每股收益(TTM)-$0,66-$0,01-60.98%

下次财报

开盘前。

预估 · 升级 →

查看财报详情 →

指标

买价
35.98
市值
354M
净利润(TTM)
-97.4M
n/a
-2.15
n/a
-3.12
市净率(TTM)
1.33
市销率(TTM)
n/a
财报日期
Nov 5, 2026
卖价
64.74
成交量
766,134
20日均量
1,913,075
开盘价
7.25
前收盘价
7.30
日内区间
7.17 - 7.55
52周区间
4.01 - 54.97
分红
n/a
除息日
n/a

关于 Sionna Therapeutics, Inc.

查看公司资料 →
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts. Biotechnology · Healthcare

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

板块 Healthcare
上市日期 Feb 7, 2025
员工人数 59
交易所 NasdaqGM
股票代码 SION